Oct 8, 2026
If you own Loblaw Companies (TSX:L) stock, then recent headlines may have you doing some happy math. Canada’s Weston family — the controlling force behind Loblaws and Shoppers Drug Mart — is reportedly close to buying Boots, the U.K.’s best-known pharmacy chain.
Private equity firm Sycamore Partners came to an agreement to sell Boots to the Canadian branch of the Weston family for about CA$12.7 billion, through the private equity firm Wittington. Closing is expected in the first quarter of 2027, according to The Guardian.
Advertisement
Boots operates roughly 1,800 stores and the deal includes U.K. and Ireland retail stores, Thailand operations, franchised businesses, the optical division and No7 Beauty Co. Sycamore and Stefano Pessina’s family will keep Farmacias Benavides and Alliance Healthcare Deutschland.
Thanks for subscribing!
The best of Money.ca delivered weekly.
By signing up, you accept Money.ca Terms of Use, Subscription Agreement, and Privacy Policy.
Here’s why investors in Loblaw Companies shares probably won’t own a piece of Boots — and what to check before you buy or sell shares of the great Canadian grocery store.
Who would actually own Boots?
Wittington Investments, a private investment company, is the confirmed buyer, according to Private Equity Wire, a trade publication covering private capital. Toronto-based Fairfax Financial Holdings (TSX:FFH) will contribute up to US$2.3 billion and hold a 50% stake after closing.
According to a Fairfax announcement, Wittington will keep operational control, Galen Weston will become Chairman for Boots, with Fairfax assuming 50% equity ownership.
These details matter.
Must Read
- A single line on your car insurance policy could be inflating your premium by up to 30% — here's what to change
- Here are 5 'must-haves' that Canadians constantly overpay for. How many of these are sabotaging your budget every single month?
- Here are the 5 biggest differences between rich and poor Canadians — which side do you fall on?
Join 20,000+ readers and get Money.ca’s best stories and exclusive interviews first — clear insights curated and delivered weekly. Subscribe now.
Can investors benefit from this acquisition?
Wittington isn’t listed on any stock exchange, so you can’t buy its shares. It sits at the top of the Weston family’s Canadian holdings and controlled by Galen G. Weston, who also holds approximately 59.2% of publicly-traded George Weston Limited (GWL) as of August 2025. GWL (TSX:WN), in turn, held 613.8 million Loblaw shares as of Mar. 28, 2026, a controlling stake, according to its first-quarter report.
What does all this mean for investors? It means the acquisition of Boots puts the asset alongside Loblaws and GWL, co-owned by private equity firm Wittington and publicly-traded Fairfax Financial Holdings. That means the Boots acquisition should have no material impact on Loblaw (TSX:L) and GWL (TSX:WN) shares. While, owning Loblaw or GWL will still give investors a slice of the Weston business, it won’t give investors a slice of the family’s overall asset mix. (Yes, pun intended.) To get access to this latest acquisition, investors would need to consider adding Fairfax Financial Holdings to their portfolio.
Could Loblaw shareholders benefit anyway?
Boots’ sales and profits will flow to Wittington and Fairfax, not into Loblaw’s or GWL’s financial results.
As a result, investors looking to cash-in on the U.K. pharmacy deal need to consider where and how these international earnings will be realized. According to a note from RBC Capital Markets analyst Irene Nattel, released on Sept. 30, the impact of this Wittington deal is expected to have little impact on Loblaw or George Weston financial results.
Advertisement
But what about the connection? The fact that U.K.-based Boots and Canada-based Shopper’s Drug Mart both sell prescriptions, beauty products and health services means there could be a partnership — and this could have knock-on effects for investors.
As Amar Singh, senior director at consultancy firm Kantar, suggested in a recent Bloomberg article, both pharmaceutical businesses should benefit as they can share infrastructure and best practices.
In a statement released by Wittingon, Galen Weston praised the acquisition, stating “We have great respect for Boots' legacy and leading market position. We see a meaningful opportunity to make a great business even better through stable long-term ownership, further capital investment, and the renewed operating focus required to serve customers with excellence for generations to come.
As of Oct. 8, 2026, the deal is signed but not closed. Closing is expected in Q1 2027.
What actually moves your Loblaw (TSX:L) shares?
For investors, the only move that matters is Loblaw’s own results.
Advertisement
In the first quarter of 2026 (12 weeks ended Mar. 28, 2026), Loblaw revenue rose 4.2% to CA$4.5 billion, and drug retails reached CA$4.2 billion, with beauty products driving front-store growth, according to GWL’s first-quarter report. The same report says Loblaw expects adjusted earnings per share to grow in the high single digits in 2026.
For investors holding GWL shares, its value is tied mostly to its Loblaw and Choice Properties stakes. GWL was trading at just over CA$100 per share as of Oct. 5, 2026 — down from CA$117.93 per share at the end of March.
In other words, grocery traffic, prescription volumes and beauty sales in Canada matter far more to your portfolio than a pharmacy deal overseas.
What investors should do
Before you act on headlines regarding a potential U.K pharmacy acquisition, investors would be wise to run through a checks and balances list:
- Don’t buy based on an announcement. The deal is signed but won’t close until early 2027, and Loblaw isn’t a party to it.
- Check official filings. Search Loblaw (TSX:L), George Weston (TSX:WN), as well as Fairfax Financial (TSX:FFH) news releases on the System for Electronic Data Analysis and Retrieval+ (SEDAR+), Canada’s public filing database. Look for details about the deal and then position your investing decision according to your plan and risk tolerance.
- Know which account holds the stock. Selling inside a tax-free savings account (TFSA) or registered retirement savings plan (RRSP) doesn’t trigger capital gains tax. Selling in a non-registered account can.
- Check your concentration. Owning both Loblaw and GWL isn’t diversification — both depend heavily on the same grocery and pharmacy business.
- Back door into Boots. Boots isn’t publicly traded, and a private sale would end the London stock listing Sycamore had considered. Perhaps the only legitimate backdoor into the Boots deal is to invest in Fairfax Financial — where shareholders will get indirect exposure once the deal closes. Just keep in mind that Fairfax is a diversified insurance and investment holding company, so Boots would be a small slice of it.
The Boots deal is a story about the Westons’ (and Fairfax’s) wealth, not your Loblaw portfolio. For Canadian investors that means judging your Loblaw or GWL position the way you would any other stock: on its earnings, its valuation and how much of your money is riding on it. If those still fit your plan, a headline from London, U.K. doesn’t need to change it.
Editorial Note: This article was updated on Oct. 8, 2026, to reflect definitive agreement where Wittington Investments, Limited ("Wittington"), the holding company of the Weston family based in Canada, would acquire Boots and its associated businesses, which are majority owned by Sycamore Partners, in partnership with Stefano Pessina and his family. The total purchase consideration is US$8.9 billion, including assumed debt.
You May Also Like
- This 7-step plan from Dave Ramsey is designed to help you ditch debt, save more and build wealth — here’s how it works
- Prioritize these 4 critical investments and watch your net worth skyrocket
- Here are 8 solid money moves that could free up real cash every month — here's where to start
- Millionaires under 43 are reshaping investing — just 25% of their portfolios are in stocks. Here’s where their money is going
The most expensive financial mistakes are often the ones you don't see coming. Join 19,000+ Canadians who get the money moves, risks and opportunities shaping their finances — delivered free each week. Subscribe now.
Romana King, Senior Editor at Money.ca, also writes for various North American publications and the RKHomeowner blog. Her book, House Poor No More, is an Amazon bestseller and five-time award winner, including the 2022 New York CPA Society's Excellence in Financial Journalism (EFJ) Book Award.
